IMV (Nasdaq:IMV;TSX:IMV), a clinical stage immuno-oncology corporation, today released its financial and operational results for the three- and nine-month period ended September 30, 2018. As quoted in the press release: “DPX-Survivac’s ability to generate novel targeted anti-cancer T cell responses continues to be a key value driver for IMV, and we believe it will be … Continued
The post IMV Announces Q3 2018 Financial Results appeared first on Investing News Network.
Original Article: IMV Announces Q3 2018 Financial Results